- Home
- PHAR vs EYPT Comparison
PHAR vs EYPT Comparison
Compare PHAR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EYPT
- Stock Information
- Founded
- PHAR 1988
- EYPT 1987
- Country
- PHAR Netherlands
- EYPT United States
- Employees
- PHAR N/A
- EYPT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PHAR Health Care
- EYPT Industrials
- Exchange
- PHAR Nasdaq
- EYPT Nasdaq
- Market Cap
- PHAR 951.7M
- EYPT 967.4M
- IPO Year
- PHAR N/A
- EYPT 2005
- Fundamental
- Price
- PHAR $14.67
- EYPT $11.12
- Analyst Decision
- PHAR Strong Buy
- EYPT Strong Buy
- Analyst Count
- PHAR 3
- EYPT 5
- Target Price
- PHAR $30.00
- EYPT $29.60
- AVG Volume (30 Days)
- PHAR 11.4K
- EYPT 1.6M
- Earning Date
- PHAR 11-06-2025
- EYPT 11-05-2025
- Dividend Yield
- PHAR N/A
- EYPT N/A
- EPS Growth
- PHAR N/A
- EYPT N/A
- EPS
- PHAR 0.00
- EYPT N/A
- Revenue
- PHAR $362,274,000.00
- EYPT $42,339,000.00
- Revenue This Year
- PHAR $17.70
- EYPT N/A
- Revenue Next Year
- PHAR $12.25
- EYPT N/A
- P/E Ratio
- PHAR $2,266.68
- EYPT N/A
- Revenue Growth
- PHAR 26.78
- EYPT N/A
- 52 Week Low
- PHAR $7.31
- EYPT $3.91
- 52 Week High
- PHAR $17.08
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- PHAR 56.76
- EYPT 42.05
- Support Level
- PHAR $12.68
- EYPT $9.65
- Resistance Level
- PHAR $13.43
- EYPT $13.32
- Average True Range (ATR)
- PHAR 0.63
- EYPT 0.85
- MACD
- PHAR 0.01
- EYPT -0.07
- Stochastic Oscillator
- PHAR 51.83
- EYPT 45.91
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.